LRNZ vs. ARKG ETF Comparison

Comparison of TrueMark Technology, AI & Deep Learning ETF (LRNZ) to ARK Genomic Revolution Multi-Sector ETF (ARKG)
LRNZ

TrueMark Technology, AI & Deep Learning ETF

LRNZ Description

LRNZ seeks to provide total return by investing in an actively managed, concentrated portfolio of companies that are significantly involved in the application of high levels of artificial intelligence. Intends to serve as a more focused alpha seeking solution to complement traditional technology-based indices Targets companies with leading-edge artificial intelligence, machine learning, or deep learning technology platforms, algorithms, or applications that we believe may provide distinct competitive advantages in an industry historically characterized by a winner-take-all consolidation behavior. Portfolio construction begins with a multi-cap investment universe comprised of secular growth companies, cyclical growth companies, and newly public companies. Actively managed by highly credentialed artificial intelligence specialist with deep field experience and robust Silicon Valley network.

Grade (RS Rating)

Last Trade

$42.84

Average Daily Volume

3,804

Number of Holdings *

19

* may have additional holdings in another (foreign) market
ARKG

ARK Genomic Revolution Multi-Sector ETF

ARKG Description Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.

Grade (RS Rating)

Last Trade

$23.83

Average Daily Volume

2,221,130

Number of Holdings *

34

* may have additional holdings in another (foreign) market
Performance
Period LRNZ ARKG
30 Days 12.15% 1.19%
60 Days 12.69% -6.00%
90 Days 11.77% -11.64%
12 Months 33.12% -13.66%
1 Overlapping Holdings
Symbol Grade Weight in LRNZ Weight in ARKG Overlap
SDGR C 1.98% 3.97% 1.98%
LRNZ Overweight 18 Positions Relative to ARKG
Symbol Grade Weight
NVDA C 11.48%
CRWD B 9.14%
IOT A 9.02%
NET B 6.41%
AMD F 5.23%
AMZN C 5.13%
ESTC C 5.12%
S B 4.91%
SNOW C 4.8%
DDOG A 4.75%
MDB C 4.7%
ZS C 4.02%
LLY F 3.72%
NVO D 3.56%
NOW A 3.55%
OKTA C 1.87%
ABCL D 0.97%
RLAY F 0.8%
LRNZ Underweight 33 Positions Relative to ARKG
Symbol Grade Weight
TWST D -8.55%
CRSP D -7.91%
RXRX F -6.86%
VCYT B -5.16%
NTRA B -5.13%
CDNA D -5.05%
ADPT C -4.25%
GH B -4.2%
BEAM D -4.17%
IONS F -3.85%
NTLA F -3.71%
TXG F -3.44%
NRIX D -3.38%
ARCT F -3.32%
PSNL D -2.22%
BFLY B -2.18%
PACB F -1.89%
ABSI F -1.83%
AMGN D -1.77%
VEEV C -1.68%
ACCD D -1.55%
ILMN D -1.28%
CERS C -1.17%
VRTX F -1.08%
INCY C -1.08%
REGN F -0.93%
CMPS F -0.79%
PRME F -0.74%
MASS F -0.66%
QSI C -0.62%
RPTX F -0.58%
EXAS D -0.49%
MRNA F -0.0%
Compare ETFs